| Literature DB >> 35355622 |
Ikhwanuliman Putera1,2, Mei Riasanti1, Lukman Edwar1, Made Susiyanti1, Ratna Sitompul1, Yulia Aziza1, Priscilla Jessica1, Andriansjah Rukmana3, Andi Yasmon3, Rina La Distia Nora1,2,4.
Abstract
Purpose: To investigate the utility of nonroutine polymerase chain reaction analysis of intraocular fluid to guide the diagnosis of infectious uveitis. Patients andEntities:
Keywords: Mycobacterium tuberculosis; aqueous humor; epidemiology; infection; ocular inflammation; vitreous humor
Year: 2022 PMID: 35355622 PMCID: PMC8958196 DOI: 10.2147/IDR.S356030
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Characteristics of Patients
| Characteristics | All Patients (n= 87) | Patients with Any Positive PCR Result (n=15) | Patients with Negative PCR Result (n=72) |
|---|---|---|---|
| Age | 40.93 ± 15.0 | 37.07 ± 11.8 | 41.74 ± 15.5 |
| Gender | |||
| Male | 49 (56.3%) | 8 (16.3%) | 41 (83.7%) |
| Female | 38 (43.7%) | 7 (18.4%) | 31 (81.6%) |
| Laterality | |||
| Unilateral | 39 (44.8%) | 7 (17.9%) | 32 (82.1%) |
| Bilateral | 48 (55.2%) | 8 (16.7%) | 40 (83.3%) |
| Presenting visual acuity (LogMar; median, IQR) | 1.77 (IQR 1.48) | 2.48 (IQR 1.18) | 1.77 (IQR 1.43) |
| Onset | |||
| Acute (≤ 90 days) | 49 (56.3%) | 7 (14.3%) | 42 (85.7%) |
| Chronic (> 90 days) | 35 (40.2%) | 8 (22.9%) | 27 (77.1%) |
| Unclear | 3 (3.4%) | 0 | 3 (100%) |
| Fluid samples | |||
| Aqueous | 80 (92.0%) | 13 (16.2%) | 67 (83.8%) |
| Vitreous | 7 (8.0%) | 2 (28.6%) | 5 (71.4%) |
| Anterior chamber cells* | |||
| < +2 | 52 (57.8%) | 8 (15.4%) | 44 (84.6%) |
| ≥ +2 | 20 (22.2%) | 4 (20.0%) | 16 (80.0%) |
Note: *Anterior chamber cells data in 15 patients were not available or could not be evaluated.
Abbreviations: PCR, polymerase chain reaction; IQR, interquartile range.
Positivity of Intraocular PCR Based on Microorganism and Anatomical Involvement
| Microorganism | N Tested | N positive (% From N Tested) | N (Eyes) Positive Based on the SUN Anatomical Classification / N (Eyes Assessed) | |||
|---|---|---|---|---|---|---|
| Anterior | Intermediate | Posterior | Panuveitis | |||
| M. tuberculosis | 72 | 5 (6.9%) | 1/11 (9.1%) | 0/3 (0%) | 1/28 (3.6%) | 3/30 (10.0%) |
| T. gondii | 37 | 3 (8.1%) | 0/3 (0%) | 0/2 (0%) | 2/15 (13.3%) | 1/17 (5.9%) |
| CMV | 55 | 3 (5.5%) | 2/5 (40.0%) | 0/3 (0%) | 1/23 (4.3%) | 0/24 (0%) |
| HSV | 41 | 1 (2.4%) | 0/3 (0%) | 0/2 (0%) | 0/15 (0%) | 1/21 (4.8%) |
| VZV | 29 | 2 (6.9%) | 0/1 (0%) | 0/2 (0%) | 2/12 (16.7%) | 0/14 (0%) |
| Rubella | 27 | 1 (3.7%) | 0/1 (0%) | 0/1 (0%) | 0/9 (0%) | 1/16 (6.3%) |
| EBV | 24 | 0 (0) | 0/1 (0%) | 0/1 (0%) | 0/9 (0%) | 0/13 (0%) |
Abbreviations: SUN, Standardization of Uveitis Nomenclature; CMV, cytomegalovirus; HSV, herpes simplex virus; VZV, varicella-zoster virus; EBV, Epstein–Barr virus.
Positivity of Intraocular PCR Based on Anatomical Involvement and Fluid Sample Type
| SUN Anatomical Involvement | Fluid Sample | Total N (Patient) Tested | N (Patient) Positive/N Total (%) | Distribution of Positive Pathogen Findings (N) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CMV | EBV | HSV | VZV | Rubella | ||||||
| Anterior | Aqueous | 11 | 3/11 (27.3%) | 1 | – | 2 | – | – | – | – |
| Vitreous | 0 | 0/0 (0%) | – | – | – | – | – | – | – | |
| Intermediate | Aqueous | 3 | 0/3 (0%) | – | – | – | – | – | – | – |
| Vitreous | 0 | 0/0 (0%) | – | – | – | – | – | – | – | |
| Posterior | Aqueous | 29 | 5/29 (17.2%) | 1 | 2 | – | – | – | 2 | – |
| Vitreous | 5 | 1/5 (20%) | – | – | 1 | – | – | – | – | |
| Panuveitis | Aqueous | 37 | 5/37 (13.5%) | 2 | 1 | – | – | 1 | – | 1 |
| Vitreous | 2 | 1/2 (50%) | 1 | – | – | – | – | – | – | |
Abbreviations: SUN, Standardization of Uveitis Nomenclature; CMV, cytomegalovirus; HSV, herpes simplex virus; VZV, varicella-zoster virus; EBV, Epstein–Barr irus.